1027 related articles for article (PubMed ID: 17694093)
41. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.
Tsapis M; Lieb M; Manzo F; Shankaranarayanan P; Herbrecht R; Lutz P; Gronemeyer H
Int J Biochem Cell Biol; 2007; 39(7-8):1500-9. PubMed ID: 17499001
[TBL] [Abstract][Full Text] [Related]
42. 3D-QSAR of histone deacetylase inhibitors as anticancer agents by genetic function approximation.
Wagh NK; Deokar HS; Juvale DC; Kadam SS; Kulkarni VM
Indian J Biochem Biophys; 2006 Dec; 43(6):360-71. PubMed ID: 17285800
[TBL] [Abstract][Full Text] [Related]
43. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Hrzenjak A; Kremser ML; Strohmeier B; Moinfar F; Zatloukal K; Denk H
J Pathol; 2008 Dec; 216(4):495-504. PubMed ID: 18850582
[TBL] [Abstract][Full Text] [Related]
44. Histone deacetylase inhibitors in myelodysplastic syndrome.
Bhalla K; List A
Best Pract Res Clin Haematol; 2004 Dec; 17(4):595-611. PubMed ID: 15494297
[TBL] [Abstract][Full Text] [Related]
45. Targeting histone deacetylase in cancer therapy.
Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
[TBL] [Abstract][Full Text] [Related]
46. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases.
Hildmann C; Wegener D; Riester D; Hempel R; Schober A; Merana J; Giurato L; Guccione S; Nielsen TK; Ficner R; Schwienhorst A
J Biotechnol; 2006 Jun; 124(1):258-70. PubMed ID: 16567013
[TBL] [Abstract][Full Text] [Related]
47. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
Flis S; Gnyszka A; Spławiński J
Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
[TBL] [Abstract][Full Text] [Related]
48. Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M; Younes A
Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
[TBL] [Abstract][Full Text] [Related]
49. Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with histone deacetylase inhibitors.
Naldi M; Calonghi N; Masotti L; Parolin C; Valente S; Mai A; Andrisano V
Proteomics; 2009 Dec; 9(24):5437-45. PubMed ID: 19834889
[TBL] [Abstract][Full Text] [Related]
50. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
51. Rational development of histone deacetylase inhibitors as anticancer agents: a review.
Acharya MR; Sparreboom A; Venitz J; Figg WD
Mol Pharmacol; 2005 Oct; 68(4):917-32. PubMed ID: 15955865
[TBL] [Abstract][Full Text] [Related]
52. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
53. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Epping MT; Bernards R
Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
[TBL] [Abstract][Full Text] [Related]
54. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
Yan C; Xiu Z; Li X; Li S; Hao C; Teng H
Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905
[TBL] [Abstract][Full Text] [Related]
55. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.
Gregoretti IV; Lee YM; Goodson HV
J Mol Biol; 2004 Apr; 338(1):17-31. PubMed ID: 15050820
[TBL] [Abstract][Full Text] [Related]
56. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
57. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
[TBL] [Abstract][Full Text] [Related]
58. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Ropero S; Fraga MF; Ballestar E; Hamelin R; Yamamoto H; Boix-Chornet M; Caballero R; Alaminos M; Setien F; Paz MF; Herranz M; Palacios J; Arango D; Orntoft TF; Aaltonen LA; Schwartz S; Esteller M
Nat Genet; 2006 May; 38(5):566-9. PubMed ID: 16642021
[TBL] [Abstract][Full Text] [Related]
59. Effect of the histone deacetylase inhibitor trichostatin a in human peripheral blood lymphocytes as a function of donor age.
Sourlingas TG; Kypreou KP; Topakas GN; Karchilaki IN; Stavropoulos-Giokas C; Sekeri-Pataryas KE
Ann N Y Acad Sci; 2007 Nov; 1119():64-71. PubMed ID: 18056955
[TBL] [Abstract][Full Text] [Related]
60. HDAC inhibitors: clinical update and mechanism-based potential.
Glaser KB
Biochem Pharmacol; 2007 Sep; 74(5):659-71. PubMed ID: 17498667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
